Interleukin-18 (IL-18) engineered for half-life extension and resistance to IL-18 binding protein (IL-18BP) to enhance anti-cancer therapeutic potential
{{output}}
Recombinant interleukin-18 (IL-18) holds promise as a therapeutic for oncology, as a robust activator of adaptive and innate immune cells and a potent producer of IFN-γ. However, clinical success has been limited due to rapid upregulation of the natural IL-18... ...
